MR-Guided Radiotherapy for Prostate Cancer

External beam radiotherapy remains the primary treatment modality for localized prostate cancer. The radiobiology of prostate carcinoma lends itself to hypofractionation, with recent studies showing good outcomes with shorter treatment schedules. However, the ability to accurately deliver hypofracti...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 10; p. 616291
Main Authors Tocco, Boris R, Kishan, Amar U, Ma, Ting Martin, Kerkmeijer, Linda G W, Tree, Alison C
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 09.12.2020
Subjects
image-guided radiotherapy
MR-guided radiotherapy
MR-linac
Oncology
online adaptive radiotherapy
prostate cancer
MR-guided radiotherapy
prostate cancer
online adaptive radiotherapy
MR-linac
image-guided radiotherapy
Online AccessGet full text

Cover

More Information
Summary:External beam radiotherapy remains the primary treatment modality for localized prostate cancer. The radiobiology of prostate carcinoma lends itself to hypofractionation, with recent studies showing good outcomes with shorter treatment schedules. However, the ability to accurately deliver hypofractionated treatment is limited by current image-guided techniques. Magnetic resonance imaging is the main diagnostic tool for localized prostate cancer and its use in the therapeutic setting offers anatomical information to improve organ delineation. MR-guided radiotherapy, with daily re-planning, has shown early promise in the accurate delivery of radiotherapy. In this article, we discuss the shortcomings of current image-guidance strategies and the potential benefits and limitations of MR-guided treatment for prostate cancer. We also recount present experiences of MR-linac workflow and the opportunities afforded by this technology.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Alessio Bruni, University Hospital of Modena, Italy
This article was submitted to Radiation Oncology, a section of the journal Frontiers in Oncology
Reviewed by: Andrea Vavassori, European Institute of Oncology (IEO), Italy; Niccolo Giaj Levra, Sacro Cuore Don Calabria Hospital, Italy
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2020.616291